The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression
Author:
Publisher
Wiley
Subject
Hematology
Reference22 articles.
1. Myelodysplastic syndromes;Tefferi;N Engl J Med,2009
2. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions;Sloand;J Clin Oncol,2010
3. Greenberg PL Attar E Bennett JM http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf.
4. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment;Frontiers in Immunology;2022-08-08
2. Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia;Cancers;2021-10-08
3. Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome;Best Practice & Research Clinical Haematology;2021-06
4. Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?;Cancers;2021-01-03
5. Evolving therapies for lower-risk myelodysplastic syndromes;Annals of Hematology;2020-02-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3